2-甲基-1,3-噻唑-4-碳酰胺盐酸盐 | 18876-82-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-甲基-1,3-噻唑-4-碳酰胺盐酸盐
• 中文别名: 2-甲基-1,3-噻唑-4-双甲脒盐酸盐
• 英文名称: 2-methylthiazole-4-carboximidamide hydrochloride
• 英文别名: 2-methyl-1,3-thiazole-4-carboximidamide Hydrochloride；2-methyl-1,3-thiazole-4-carboximidamide;hydrochloride
• CAS: 18876-82-9
• 化学式: C₅H₇N₃S*ClH
• 分子量: 177.658
• InChiKey: YYLYRAUCGUIGIE-UHFFFAOYSA-N

物化性质

• 熔点：
  185 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.16
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  91
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S23,S36/37/39
• 危险类别码：
  R20/21/22
• 海关编码：
  2934100090

SDS

Name:	2-Methyl-1 3-thiazole-4-carboximidamide hydrochloride 97% Material Safety Data Sheet
Synonym:	2-Methylthiazole-4-carboxamidine hydrochlorid
CAS:	18876-82-9

Section 1 - Chemical Product MSDS Name:2-Methyl-1 3-thiazole-4-carboximidamide hydrochloride 97% Material Safety Data Sheet
Synonym:2-Methylthiazole-4-carboxamidine hydrochlorid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
18876-82-9	2-Methyl-1,3-thiazole-4-carboximidamid	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 18876-82-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 185 - 189 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H8ClN3S
Molecular Weight: 178

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 18876-82-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Methyl-1,3-thiazole-4-carboximidamide hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 18876-82-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 18876-82-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 18876-82-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  β-羟基异戊酸 、 2-甲基-1,3-噻唑-4-碳酰胺盐酸盐 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Rapid Synthesis of 1,3,5-Substituted 1,2,4-Triazoles from Carboxylic Acids, Amidines, and Hydrazines

  摘要：

  A general method for the synthesis of 1,3,5-trisubstituted 1,2,4-triazoles has been developed from reaction of carboxylic acids, primary amidines, and monosubstituted hydrazines. This highly regioselective and one-pot process provides rapid access to highly diverse triazoles.

  DOI：

  10.1021/jo1023393
• 作为产物：
  描述：

  2-甲基-1,3-噻唑-4-甲腈 在 sodium methylate 、 氯化铵 作用下， 以 甲醇 、 水 为溶剂， 反应 5.0h， 以491 g的产率得到2-甲基-1,3-噻唑-4-碳酰胺盐酸盐
  参考文献：
  名称：

  的发现ñ - [双（4-甲氧基苯基）甲基] -4-羟基-2-（哒嗪-3-基）嘧啶-5-甲酰胺（MK-8617），缺氧诱导因子脯氨酰的口服活性泛抑制剂羟化酶1-3（HIF PHD1-3）用于治疗贫血

  摘要：

  描述了新型的缺氧诱导因子（HIF）脯氨酰羟化酶（PHD）的4-羟基-2-（杂环）嘧啶-5-羧酰胺抑制剂的发现。这些在多个物种中均有效，选择性，口服生物利用，并在刺激促红细胞生成中起作用。小鼠和大鼠研究表明，单次口服给药后，血浆血浆EPO和循环网织红细胞升高会引起血液学变化，而大鼠连续4天qd po给药后血红蛋白水平升高。优化过程的主要重点是减少早期化合物在较高物种中观察到的长半衰期。这些努力导致了28（MK-8617）的鉴定，该鉴定已用于贫血的人类临床试验。

  DOI：

  10.1021/acs.jmedchem.6b01242

文献信息

• Intercepted Retro-Nazarov Reaction: Syntheses of Amidino-Rocaglate Derivatives and Their Biological Evaluation as eIF4A Inhibitors
  作者：Wenhan Zhang、Jennifer Chu、Andrew M. Cyr、Han Yueh、Lauren E. Brown、Tony T. Wang、Jerry Pelletier、John A. Porco

  DOI：10.1021/jacs.9b06446

  日期：2019.8.14

  rocaglate skeleton. Trapping of the oxyallyl cation with a diverse range of nucleophiles has been used to generate over fifty novel amidino-rocaglate (ADR) and amino-rocaglate derivatives. Subsequently, these derivatives were evaluated for their ability to inhibit cap-dependent protein synthesis where they were found to outperform previous lead compounds including the rocaglate hydroxamate CR-1-31-B.

  Rocaglates 是从米兰属中分离出来的一类天然产物，具有高度取代的环戊[b]苯并呋喃骨架，可抑制帽子依赖性蛋白质合成。Rocaglalate 是一种颇具吸引力的化合物，因为它们具有通过特异性靶向真核起始因子 4A (eIF4A) 并干扰核糖体募集至 mRNA 来抑制体内肿瘤细胞维持的潜力。在本文中，我们描述了一种截获的逆纳扎罗夫反应，利用分子内甲苯磺酰迁移在罗卡格特骨架上生成反应性氧化烯丙基阳离子。用多种亲核试剂捕获氧烯丙基阳离子已被用来生成五十多种新型脒基罗卡酸盐 (ADR) 和氨基罗卡酸盐衍生物。随后，对这些衍生物抑制帽子依赖性蛋白质合成的能力进行了评估，结果发现它们优于以前的先导化合物，包括罗卡格酯异羟肟酸 CR-1-31-B。
• NOVEL PYRIMIDINE DERIVATIVE AND NOVEL PYRIDINE DERIVATIVE
  申请人：Ajinomoto Co., Inc.

  公开号：EP1318147A1

  公开（公告）日：2003-06-11

  Achiral pyrimidine derivatives and pyridine derivatives of the following formulae or analogs thereof have selective N-type calcium channel antagonistic activity and showed analgesic action when they were taken orally. They are useful as therapeutic agents for pains and various diseases associated with the N-type calcium channels.

  非手性嘧啶衍生物和以下结构式或其类似物的吡啶衍生物具有选择性N型钙通道拮抗活性，并且当口服时表现出镇痛作用。它们可用作与N型钙通道相关的疼痛和各种疾病的治疗药物。
• Traceless solid phase synthesis of 2-substituted pyrimidines using an ‘off-the-shelf’ chlorogermane-functionalised resin
  作者：Alan C. Spivey、Ratnasothy Srikaran、Christopher M. Diaper、David J. Turner

  DOI：10.1039/b303064d

  日期：——

  The parallel solid phase synthesis of an 18-member library of 2-substituted pyrimidines is described using a chlorogermane-functionalised resin. The success of the key Pinner-type condensations between a resin-bound enaminone and an array of amidine hydrochlorides highlights the stability of arylgermane linkers (cf. arylsilanes) towards strongly basic/nucleophilic conditions.

  本文描述了使用含氯锗功能化树脂进行的18种2-取代嘧啶的平行固相合成。树脂结合的烯胺酮与一系列氨基脲盐酸盐之间关键的Pinner型缩合反应的成功，突显了芳基锗连接子（相对于芳基硅烷）在强碱性/亲核性条件下的稳定性。
• Pyrimidine derivatives and new pyridine derivatives
  申请人：AJINOMOTO CO., INC.

  公开号：US20040009991A1

  公开（公告）日：2004-01-15

  Achirai pyrimidine derivatives and pyridine derivatives of the following formulae or analogs thereof have selective N-type calcium channel antagonistic activity and showed analgesic action when they were taken orally. They are useful as therapeutic agents for pains and various diseases associated with the N-type calcium channels. 1

  Achirai嘧啶衍生物和以下结构式或其类似物的吡啶衍生物具有选择性N型钙通道拮抗活性，并在口服时显示镇痛作用。它们可用作与N型钙通道相关的疼痛和各种疾病的治疗药物。
• Efficient synthesis of highly functionalized tetrahydropyridopyrimidines by a novel three-component coupling reaction
  作者：Izzat T. Raheem、John D. Schreier、Michael J. Breslin

  DOI：10.1016/j.tetlet.2011.05.071

  日期：2011.7

  We report the development of a novel three-component coupling reaction (3CC) for the synthesis of alkoxy tetrahydropyridopyrimidines. Systematic optimization of reaction parameters identified 3CC conditions tolerant of a wide array of functionality at all three sites of diversity, providing densely functionalized products in moderate to excellent yields. The newly developed chemistry has since been

  我们报告了合成烷氧基四氢吡啶并嘧啶类化合物的新型三组分偶联反应（3CC）的发展。反应参数的系统优化确定了在所有三个多样性位点都能耐受多种功能的3CC条件，从而以中等到极好的收率提供了功能密集的产品。此后，新开发的化学方法已应用于新型药物发现程序中的前导优化过程，从而促进了化合物的快速开发。